Wilms tumor protein peptide–major histocompatibility complex (WT1 peptide–MHC complex)

The Wilms tumor protein peptide–major histocompatibility complex (WT1 peptide–MHC complex) is a molecular assembly in which a peptide derived from the Wilms tumor protein 1 (WT1) is bound and presented on the surface of cells in association with a major histocompatibility complex (MHC) class I molecule (such as HLA-A*24:02). This complex functions as an immune "beacon," allowing cytotoxic T lymphocytes to recognize and selectively target cells expressing WT1, including many types of tumor cells. Mechanistically, the WT1–MHC complex is fundamental to anti-tumor immunosurveillance and serves as a key antigen for T cell-based immunotherapies in cancer. Stable formation of these complexes is essential for efficient recognition by T cell receptors; much effort in immunotherapy research is devoted to engineering peptides and MHC molecules to increase stability and specificity for tumor antigens such as WT1[1][2][5]. The clinical rationale for targeting this complex includes the high, often selective expression of WT1 in various malignancies, and the ability to harness or augment patient immune responses against these targets. Challenges include ensuring tumor specificity, preventing immune escape, and minimizing toxicity to normal tissues.

Other names

Wilms tumor 1 peptide–MHC complexWT1 peptide–MHCmWT1–MHC complexpeptide–MHC (WT1)WT1 antigen–MHC complex

Engagement of T cell receptors on cytotoxic T cells leads to recognition and killing of cells presenting the WT1 peptide-MHC complex[1][2]. Used for immune targeting via engineered TCRs or vaccine-induced T cell responses.